title: Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network.
abstract: The Clinical Immunization Safety Assessment (CISA) Network is a collaboration between the Centers for Disease Control and Prevention (CDC) and 6 academic medical centers to provide support for immunization safety assessment and research. The CISA Network was established by the CDC in 2001 with 4 primary goals: (1) develop research protocols for clinical evaluation, diagnosis, and management of adverse events following immunization (AEFI); (2) improve the understanding of AEFI at the individual level, including determining possible genetic and other risk factors for predisposed people and subpopulations at high risk; (3) develop evidence-based algorithms for vaccination of people at risk of serious AEFI; and (4) serve as subject-matter experts for clinical vaccine-safety inquiries. CISA Network investigators bring in-depth clinical, pathophysiologic, and epidemiologic expertise to assessing causal relationships between vaccines and adverse events and to understanding the pathogenesis of AEFI. CISA Network researchers conduct expert reviews of clinically significant adverse events and determine the validity of the recorded diagnoses on the basis of clinical and laboratory criteria. They also conduct special studies to investigate the possible pathogenesis of adverse events, assess relationships between vaccines and adverse events, and maintain a centralized repository for clinical specimens. The CISA Network provides specific clinical guidance to both health care providers who administer vaccines and those who evaluate and treat patients with possible AEFI. The CISA Network plays an important role in providing critical immunization-safety data and expertise to inform vaccine policy-makers. The CISA Network serves as a unique resource for vaccine-safety monitoring efforts conducted at the CDC.
authors.affiliation: Department of Pediatrics, Division of Pediatric Infectious Diseases, Columbia University, New York, NY, USA. plarussa@columbia.edu
authors.forename: Philip S
authors.initials: PS
authors.lastname: LaRussa
authors.forename: Kathryn M
authors.initials: KM
authors.lastname: Edwards
authors.forename: Cornelia L
authors.initials: CL
authors.lastname: Dekker
authors.forename: Nicola P
authors.initials: NP
authors.lastname: Klein
authors.forename: Neal A
authors.initials: NA
authors.lastname: Halsey
authors.forename: Colin
authors.initials: C
authors.lastname: Marchant
authors.forename: Roger
authors.initials: R
authors.lastname: Baxter
authors.forename: Renata J M
authors.initials: RJ
authors.lastname: Engler
authors.forename: Jennifer
authors.initials: J
authors.lastname: Kissner
authors.forename: Barbara A
authors.initials: BA
authors.lastname: Slade
mesh_terms: D000046:Academic Medical Centers; D016907:Adverse Drug Reaction Reporting Systems; D002487:Centers for Disease Control and Prevention, U.S.; D032882:Comprehension; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006266:Health Education / Q000379:methods; D006801:Humans; D007114:Immunization / Q000009:adverse effects / Q000379:methods; D007255:Information Services; D008297:Male; D018570:Risk Assessment; D012380:Role; D017751:Safety Management; D014481:United States; D014611:Vaccination / Q000009:adverse effects* / Q000379:methods; D014612:Vaccines / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D014612:Vaccines